CXCR4 and CCR5 expression on CD4+ T cells in vivo and HIV-1 antigen β- chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE)

Journal of Human Virology

Volumn 3, Issue 1, 2000, Pages 44-49

  Moss, Ronald B ^a   Giermakowska, Wieslawa K ^a   Diveley, Jocelyn P ^a   Savary, Jay R ^a   Wallace, Mark R ^b   Maigetter, Robert Z ^a   Jensen, Fred C ^a   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

^b Space and Naval Warfare Systems Center Pacific   (United States)

Author keywords

Beta chemokine; CCR5; REMUNE

Indexed keywords

BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE ACTIVATION;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHEMOKINES, CC; DOWN-REGULATION; HIV ANTIGENS; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; VACCINES, SYNTHETIC;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033910318     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. + T cells. Science 1995;270:1811-1815.
2. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273:1856-1862.
3. Garzino-Demo A, DeVico AL, Cocchi F, Gallo RC. β-Chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 1998;14(Suppl 2):S177-S184.
4. Ostrowski MA, Justement SJ, Catanzaro A, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998; 161:3195-3201.
5. Lehner T, Wang Y, Cranage M, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996;2:767-775.
6. Wang Y, Tao L, Mitchell E, et al. Generation of CD8 suppressor factor and beta-chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques. Proc Natl Acad Sci USA 1998;95:5223-5228.
7. Eugen-Olsen J, Iversen AKN, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11:305-310.
8. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86: 367-377.
9. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;22: 722-725.
10. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
11. Zimmerman PA, Bucklerwhite A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor-5 studies in populations with contrasting clinical phenotypes, defined racial backgrounds, and quantified risk. Mol Med 1997;3:23-36.
12. Moss RB, Ferre F, Trauger RJ, et al. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. AIDS 1994;7:S21-S27.
13. Moss RB, Wallace MR, Lanza P, et al. In vitro p24 antigen-stimulated lymphocyte proliferation and -chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin Diagn Lab Immunol 1998;5:308-312.
14. Prior CP, Gore R, Harter J, et al. Inactivation and purification of human immunodeficiency virus-1 as antigen for the treatment of HIV-1 infection. BioPharm 1996;9:22-34.
15. Prior C, Bay P, Ebert B, et al. Process development for the manufacture of inactivated HIV-1. Pharm Technol 1995; 19:30-52.
16. Choi DJ, Dube S, Spicer TP, Slade HB, Jensen FC, Poiesz BJ. Sequence note: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses 1997;13:357-361.
17. Getchell JP, Hicks DR, Srinivasan A, et al. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis 1987;156:833-837.
18. LoGrippo GA. Investigations of the use of betapropiolactone in virus inactivation. Ann NY Acad Sci 1960;83:578-594.
19. Kitchen AD, Mann GF, Harrison JF, Zuckerman AJ. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox Sang 1989; 56:223-229.
20. Moss RB, Wallace MR, Giermakowska WK, et al. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis 1999;180:641-648.
21. Mosier DE, Picchio GR, Gulizia RJ, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999;73:3544-3550.
22. + T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nat Med 1999; 5:1004-1009.
23. Jiang Y, Jolly PE. Effect of beta-chemokines on human immunodeficiency virus type replication, binding, uncoating, and CCR5 receptor expression in human monocyte-derived macrophages. J Hum Virol 1999;2:123-132.
24. + T lymphocytes in HIV-infected patients treated with interleukin-2: ANRS 048 IL-2 Study Group. AIDS 1999;13:455-463.
25. Blanco J, Cabrera C, Jou A, Ruiz L, Clotet B, Este JA. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 1999; 13:547-555
26. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999;163: 4597-4603.
27. Sei S, Sandelli SL, Theofan G, et al. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. J Infect Dis 1999; 180:626-640.
28. Garzino-Demo A, Moss RB, Margolick JB, et al. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999;96:11986-11991.